GlassScriptPhysician profile
Melanie Kirk
NPI 1285972406
$3,287.67
in general payments reported to CMS, 2019-2025
23 companies · $30.97 in 2025
The $30.97 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,263 · 2022: $931 · 2023: $479 · 2024: $584 · 2025: $30.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,292.71 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $393.10 | 2021-2024 | Entyvio |
| Nestle Healthcare Nutrition INC. | $389.25 | 2021-2023 | |
| Janssen Biotech, INC. | $382.27 | 2021-2024 | Stelara, Simponi Aria, Remicade |
| Pfizer INC. | $172.14 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $83.44 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $80.45 | 2022-2023 | Linzess |
| Genzyme Corporation | $64.80 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.55 | 2022-2024 | Xifaxan, Trulance |
| Qol Medical, LLC | $53.07 | 2024 | Sucraid |
| Redhill Biopharma INC. | $47.82 | 2021 | |
| Braintree Laboratories, INC. | $40.38 | 2022 | |
| Ardelyx, INC. | $38.93 | 2024 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $30.97 | 2025 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $24.94 | 2024 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20.29 | 2021 | |
| Lilly USA, LLC | $20.04 | 2024 | Omvoh |
| Celgene Corporation | $18.21 | 2024 | Zeposia |
| Evoke Pharma, INC. | $15.64 | 2024 | |
| Intra-Sana Laboratories | $15.21 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Exact Sciences Corporation | $14.81 | 2024 | Cologuard Collection Kit |
| Medline Industries LP | $14.17 | 2023 | Medline Industries, INC., Remedy Antifungal |
| Organon LLC | $13.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.